ITHACA, N.Y.–(BUSINESS WIRE)–Jan 29, 2021–
Rheonix Inc. today announced the appointment of Roy Proujansky, M.D., and Irving Nachamkin, DrPH, MPH, to its board of directors.
"I’m honored to welcome Drs. Proujansky and Nachamkin to our board," said Greg Galvin, Ph.D., founder and CEO of Rheonix. "They join Rheonix at an exciting time as we provide critical testing solutions to address the pandemic and broaden our clinical diagnostic portfolio. The addition of these directors complements our board of directors’ skills and experiences, and we are confident they will provide valuable perspectives as we continue to execute our growth strategy.”
Dr. Proujansky is an experienced healthcare physician executive, having served for over 30 years in physician, hospital and health system leadership positions. While at Nemours Children’s Health System, his roles included chief executive for the physician practice, chief operating officer for the Nemours Children’s Health System and chief executive for the duPont Hospital for Children and Delaware Valley Operations. Dr. Proujansky has previously served as a board member of the Delaware Healthcare Association, the Delaware Health Sciences Alliance and as a member of the Children’s Hospital Association’s quality and safety committee. Dr. Proujansky received his undergraduate and medical degrees from Northwestern University and an MBA from the University of Massachusetts. He completed training in pediatrics at the University of Connecticut and fellowships in gastroenterology and nutrition and infectious disease research at Harvard Medical School. He is a professor of pediatrics at the Sidney Kimmel College of Medicine of Thomas Jefferson University.
“I’m thrilled to join Rheonix, a company that is providing accurate and low-cost diagnostic capability to clinics, hospitals and other laboratories at a time of such great need,” said Dr. Proujansky.
Dr. Nachamkin is professor emeritus of pathology and laboratory medicine and the immediate past director of the division of laboratory medicine and associate director of the clinical microbiology laboratory at the Perelman School of Medicine and Hospital of the University of Pennsylvania in Philadelphia. Dr. Nachamkin has been the principal or co-principal investigator of numerous research programs while at Penn and author or co-author of over 220 peer-reviewed papers, reviews and book chapters. He is an expert in clinical microbiology with a focus on laboratory diagnostics, molecular diagnostics in infectious diseases and laboratory management. He received his undergraduate degree in medical laboratory science from the University of Bridgeport and his MPH and DrPH from the University of North Carolina. He completed postgraduate training as a fellow in medical and public health laboratory microbiology at the Medical College of Virginia and at the Penn Medicine Clinical Leadership Academy. Dr. Nachamkin is a fellow of the American Academy of Microbiology, Infectious Diseases Society of America and College of Physicians of Philadelphia.
“It’s an honor to join the Rheonix board of directors and work with a fabulous team dedicated to improving laboratory diagnostics with exciting testing platforms and an expanded portfolio of tests,” said Dr. Nachamkin.
In April 2020, Rheonix received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx assay, a fully automated testing solution that delivers same-day results in authorized testing laboratories. In December 2020, Rheonix received expanded EUA for saliva as a sample type, enabling simplified, safer and less expensive sample collection. In order to meet evolving COVID-19 testing demand, Rheonix has increased production capacity by greater than thirtyfold.
About Emergency Use Authorization Status:
The Rheonix COVID-19 MDx Assay is an endpoint RT-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory and saliva samples from individuals who are suspected of COVID-19 by their healthcare provider. The Rheonix COVID-19 MDx Assay has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Rheonix has developed the suite of Encompass workstations, fully automated systems that provide highly multiplexed sample-to-answer molecular testing for use in clinical, research and applied testing laboratories. With minimal hands-on time, the Encompass systems offer true walkaway simplicity. Rheonix’s growing portfolio offers multiplexed testing solutions including the Beer SpoilerAlert™ assay, the most comprehensive beer spoilage panel available; the Listeria PatternAlert™ assay, a rapid method for Listeria strain typing; and the NGS OnePrep™ solution, a fully integrated and automated DNA extraction and library prep solution. The Rheonix STI TriPlex™ Assay and Rheonix Encompass MDx ® workstation are currently undergoing FDA 510(k) review. For more information, visit www.rheonix.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210129005358/en/
CONTACT: Lindsey Smith
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: FDA HEALTH INFECTIOUS DISEASES RESEARCH SCIENCE BIOTECHNOLOGY
SOURCE: Rheonix Inc.
Copyright Business Wire 2021.
PUB: 01/29/2021 09:41 AM/DISC: 01/29/2021 09:41 AM
ITHACA, N.Y.–(BUSINESS WIRE)–Jan 29, 2021–